In newly diagnosed multiple myeloma, standard initial therapy includes bortezomib, lenalidomide, and dexamethasone (VRd). But patients on VRd often develop peripheral neuropathy that can interfere with long-term therapy. And, while 4-year survival may be as high as 80 percent (N Engl J Med 2017;376:1311-1320), most patients eventually relapse.
An abstract is unavailable.
An abstract is unavailable.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Wolters Kluwer (“we” or “us”) wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain…
An abstract is unavailable.
Answer each quiz question to better understand the patient’s journey and determine the correct diagnosis. Wolters Kluwer (“we” or “us”) wants to inform you about…
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
